Loading...
Market
What will be the outcome of Phase 1 human trials of Oxford University's Marburg virus vaccine by December 31, 2024?
2
Resolution / Starting Odds
Successful • 25%
Partially successful • 25%
Unsuccessful • 25%
No results announced • 25%
Official announcements from Oxford University or reputable news sources such as BBC
Story
Oxford University Begins Human Testing of Marburg Virus Vaccine on July 12: BBC
Jul 12, 2024, 05:04 AM
Scientists at Oxford University have commenced human testing of a vaccine for the Marburg virus on July 12. This development, reported by BBC, marks a significant step in combating the deadly virus, which has been a concern for global health authorities due to its high mortality rate and potential for outbreaks. The Marburg virus is related to the Ebola virus and causes severe hemorrhagic fever in humans. The vaccine aims to provide immunity and prevent future outbreaks, contributing to global health security.
View original story
Similar markets
Successful • 25%
Partially Successful • 25%
Unsuccessful • 25%
No Results Released • 25%
Effective • 25%
Moderately Effective • 25%
Ineffective • 25%
Halted • 25%
Positive • 25%
Negative • 25%
Mixed • 25%
Not published • 25%
Successful with strong immune response • 25%
Moderate success • 25%
No significant effect • 25%
Trial halted • 25%
Successful with no major side effects • 25%
Successful with some side effects • 25%
Unsuccessful • 25%
Inconclusive • 25%
Yes • 50%
No • 50%
Successful containment • 25%
Partial containment • 25%
No containment • 25%
Worsening outbreak • 25%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Not started • 25%
Highly effective • 25%
Moderately effective • 25%
Slightly effective • 25%
Ineffective • 25%
